United States Patent [19]

Pitt et al.

[11] **4,148,871**

[45] **Apr. 10, 1979**

[54] **SUSTAINED SUBDERMAL DELIVERY OF DRUGS USING POLY(ε-CAPROLACTONE) AND ITS COPOLYMERS**

[76] Inventors: **Colin G. Pitt; Anton E. Schindler,** both of RTI, P. O. Box 12194, Research Triangle Park, N.C. 27709

[21] Appl. No.: **840,989**

[22] Filed: **Oct. 11, 1977**

[51] **Int. Cl.**[2] **A61K 31/74;** A61K 9/52

[52] **U.S. Cl.** **424/19;** 128/260; 424/21; 424/22

[58] **Field of Search** ..... 424/14–22, 424/78; 128/260, 335.5; 260/78.3 R, 78.3 UA

[56] **References Cited**

U.S. PATENT DOCUMENTS

2,890,208	6/1959	Young et al.	260/878 R
3,021,309	2/1962	Cox	260/78.3 R
3,773,919	11/1973	Boswell et al.	424/19
3,887,699	6/1975	Yolles	424/19
3,991,766	11/1976	Schmitt et al.	424/19 X

Primary Examiner—Shep K. Rose

Attorney, Agent, or Firm—Holman & Stern

[57] **ABSTRACT**

Compositions containing either poly(ε-caprolactone) or copolymers of ε-caprolactone with other lactones, together with a drug, when subdermally implanted in the body, provide a slow sustained release of the drug. The polymers may be designed to biodegrade during or subsequent to the depletion of the drug.

15 Claims, 2 Drawing Figures